Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2020 08:00 ET | Source: BioSight Ltd.

Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting

Expanded data set supports efficacy across key measures including complete remission and MRD(-) rates, duration of response and overall survival Durable responses achieved as monotherapy with...
December 02, 2020 08:00 ET | Source: BioSight Ltd.

Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

AIRPORT CITY, Israel, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
November 05, 2020 10:15 ET | Source: BioSight Ltd.

Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting

AIRPORT CITY, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
August 04, 2020 08:00 ET | Source: BioSight Ltd.

Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia

AIRPORT CITY, Israel, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
July 21, 2020 08:30 ET | Source: BioSight Ltd.

Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies

AIRPORT CITY, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
May 26, 2020 08:30 ET | Source: BioSight Ltd.

Biosight to Present at the Jefferies 2020 Virtual Healthcare Conference

AIRPORT CITY, Israel, May 26, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
May 18, 2020 09:00 ET | Source: BioSight Ltd.

Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.

AIRPORT CITY, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
March 11, 2020 09:44 ET | Source: BioSight Ltd.

Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs

AIRPORT CITY, Israel, March 11, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...